GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (LTS:0HNC) » Definitions » Cyclically Adjusted PS Ratio

Biomarin Pharmaceutical (LTS:0HNC) Cyclically Adjusted PS Ratio : 5.08 (As of Jun. 03, 2025)


View and export this data going back to 2018. Start your Free Trial

What is Biomarin Pharmaceutical Cyclically Adjusted PS Ratio?

As of today (2025-06-03), Biomarin Pharmaceutical's current share price is $57.0476. Biomarin Pharmaceutical's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was $11.24. Biomarin Pharmaceutical's Cyclically Adjusted PS Ratio for today is 5.08.

The historical rank and industry rank for Biomarin Pharmaceutical's Cyclically Adjusted PS Ratio or its related term are showing as below:

LTS:0HNC' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 4.95   Med: 12.79   Max: 44.11
Current: 4.97

During the past years, Biomarin Pharmaceutical's highest Cyclically Adjusted PS Ratio was 44.11. The lowest was 4.95. And the median was 12.79.

LTS:0HNC's Cyclically Adjusted PS Ratio is ranked better than
52.82% of 496 companies
in the Biotechnology industry
Industry Median: 5.54 vs LTS:0HNC: 4.97

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Biomarin Pharmaceutical's adjusted revenue per share data for the three months ended in Mar. 2025 was $3.793. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $11.24 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Biomarin Pharmaceutical Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Biomarin Pharmaceutical's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical Cyclically Adjusted PS Ratio Chart

Biomarin Pharmaceutical Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.73 11.16 11.49 9.59 5.91

Biomarin Pharmaceutical Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.38 7.72 6.43 5.91 6.16

Competitive Comparison of Biomarin Pharmaceutical's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Biomarin Pharmaceutical's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biomarin Pharmaceutical's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biomarin Pharmaceutical's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Biomarin Pharmaceutical's Cyclically Adjusted PS Ratio falls into.


;
;

Biomarin Pharmaceutical Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Biomarin Pharmaceutical's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=57.0476/11.24
=5.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biomarin Pharmaceutical's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Biomarin Pharmaceutical's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=3.793/134.9266*134.9266
=3.793

Current CPI (Mar. 2025) = 134.9266.

Biomarin Pharmaceutical Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 1.559 100.684 2.089
201509 1.296 100.392 1.742
201512 1.414 99.792 1.912
201603 1.465 100.470 1.967
201606 1.846 101.688 2.449
201609 1.669 101.861 2.211
201612 1.742 101.863 2.307
201703 1.759 102.862 2.307
201706 1.821 103.349 2.377
201709 1.908 104.136 2.472
201712 2.042 104.011 2.649
201803 2.120 105.290 2.717
201806 2.108 106.317 2.675
201809 2.207 106.507 2.796
201812 1.976 105.998 2.515
201903 2.248 107.251 2.828
201906 2.166 108.070 2.704
201909 2.480 108.329 3.089
201912 2.531 108.420 3.150
202003 2.682 108.902 3.323
202006 2.376 108.767 2.947
202009 2.412 109.815 2.964
202012 2.486 109.897 3.052
202103 2.636 111.754 3.183
202106 2.706 114.631 3.185
202109 2.231 115.734 2.601
202112 2.450 117.630 2.810
202203 2.665 121.301 2.964
202206 2.848 125.017 3.074
202209 2.723 125.227 2.934
202212 2.889 125.222 3.113
202303 3.069 127.348 3.252
202306 3.053 128.729 3.200
202309 3.041 129.860 3.160
202312 3.428 129.419 3.574
202403 3.256 131.776 3.334
202406 3.551 132.554 3.615
202409 3.783 133.029 3.837
202412 3.798 133.157 3.848
202503 3.793 134.927 3.793

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Biomarin Pharmaceutical  (LTS:0HNC) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Biomarin Pharmaceutical Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Biomarin Pharmaceutical's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomarin Pharmaceutical Business Description

Address
770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.

Biomarin Pharmaceutical Headlines

No Headlines